Down 24% In A Month, Will Arvinas Stock Rebound?
- Thursday, June 2, 2022, 7:20
- Market
- Add a comment
The stock price of Arvinas (NASDAQ: ARVN), a biopharmaceuticals company focused on oncology treatments based on targeted protein degradation, has fallen 24% in a month, while it’s down a significant 49% YTD.
About the Author
admin123 has written 23518 stories on this site.
